Method for treating weight loss in patients suffering from inflammatory bowel diseases
The present invention relates to a method of treating or preventing weight loss of patients with inflammatory bowel diseases comprising administering to said patients an effective amount of Saccharomyces boulardii.
1. A method of treating weight loss and reducing colonic interferon-gamma (IFN-γ) secretion in a patient having an inflammatory bowel disease (IBD) comprising administering to the patient an effective amount of Saccharomyces boulardii ( S. boulardii ) to reduce weight loss and to reduce colonic IFN-γ secretion, wherein the patient's weight loss is due to chronic inflammatory lesions of the patient's intestinal tract consecutive to an activation of the intestinal immune system.
2. The method according to claim 1 , wherein the patient has Crohn's disease.
3. The method according to claim 1 , wherein S. boulardii is in the form of a lyophilisate.
4. The method according to claim 1 , wherein S. boulardii is in the form of a lyophilisate obtained by culturing S. boulardii cells, as deposited with the American Type Culture Collection (ATCC) as Accession Number 74012 or Accession Number CNCM I-745, in a nutritive medium until the cells reach a stationary phase; concentrating the cultured S. boulardii cells to obtain a concentrate and freezing the concentrate to obtain a frozen concentrate; and vacuum drying the frozen concentrate.
5. The method according to claim 1 , wherein S. boulardii is administered orally.
6. The method according to claim 1 , wherein S. boulardii is administered in the form of tablets, capsules, dragees, sachets or suspensions.
7. The method according to claim 1 , wherein the S. boulardii is administered as a daily dosage of about 1 mg/kg to about 100 mg/kg.
8. A method of treating weight loss and reducing colonic IFN-γ secretion in a patient having Crohn's disease comprising
administering to the patient an effective amount of Saccharomyces boulardii ( S. boulardii ) to reduce weight loss and to reduce colonic IFN-γ secretion, wherein said Crohn's disease is of a severity to induce weight loss.
9. The method according to claim 8 , further comprising administering to said patient a drug selected from the group consisting of corticosteroids, prednisolone, hydrocortisone, budesonide, aminosalicylates, sulfasalazine, mesalazine, immunosuppressants, azathioprine, 6-mercaptopurine, methotrexate, ciclosporin, thalidomide, mycophenolate mofetil, anti-tumor necrosis factor(anti-TNFα) monoclonal antibodies, and infliximab.
10. The method according to claim 8 , wherein S. boulardii is in the form of a lyophilisate.
11. The method according to claim 8 , wherein S. boulardii is administered orally.
12. The method according to claim 8 , wherein the S. boulardii are ATCC Accession Number 74012 or ATCC Accession Number CNCM I-745 S. boulardii cells.
13. The method of claim 7 , wherein the daily dosage is about 10 mg/kg.